Oculis Holding Gestione

Gestione criteri di controllo 0/4

Oculis Holding Il CEO è Riad Sherif, nominato in Dec2017, ha un mandato di 6.92 anni. possiede direttamente 2.09% delle azioni della società, per un valore di € 12.89M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.8 anni e 2 anni.

Informazioni chiave

Riad Sherif

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	6.9yrs
Proprietà del CEO	2.1%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Riad Sherif (56 yo)

6.9yrs

Mandato

Dr. Riad Sherif, MD, MBA, has been the Chief Executive Officer and Director of Oculis Holding AG (formerly known as Oculis SA) since December 2017. He is Chief Executive Officer and Director of Oculis ehf....

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Riad Sherif	CEO & Director	6.9yrs	Nessun dato	2.09% € 12.9m
Sylvia Cheung	Chief Financial Officer	4.2yrs	Nessun dato	0.16% € 980.1k
Gudrun Bachmann	Chief Technology Officer	less than a year	Nessun dato	Nessun dato
Ramin Tadayoni	Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Daniel Char	Chief Legal Officer	less than a year	Nessun dato	Nessun dato
Virginia Dean	Chief Human Resources Officer	less than a year	Nessun dato	Nessun dato
Páll Jóhannesson	Chief Business Officer	4.2yrs	Nessun dato	0.59% € 3.7m
Rebecca Weil	Chief Commercial Officer	1.2yrs	Nessun dato	Nessun dato
Snehal Shah	President of Research & Development	less than a year	Nessun dato	Nessun dato
Sharon Klier	Chief Development Officer	less than a year	Nessun dato	Nessun dato
Isabelle de Chambrier	Senior Vice President of Quality	1.2yrs	Nessun dato	Nessun dato

0.8yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di CR5 non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Riad Sherif	CEO & Director	6.9yrs	Nessun dato	2.09% € 12.9m
Eric Donnenfeld	Chair of Cornea Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anthony Rosenberg	Independent Chairman	6.6yrs	Nessun dato	0.23% € 1.4m
Christophe Baudouin	Member of Scientific Advisory Board	2yrs	Nessun dato	Nessun dato
Peter Kaiser	Member of Scientific Advisory Board	2yrs	Nessun dato	Nessun dato
Lionel Carnot	Independent Director	6.9yrs	Nessun dato	Nessun dato
Christina Ackermann	Independent Director	1.7yrs	Nessun dato	0.028% € 171.9k
Quan Dong Nguyen	Member of Scientific Advisory Board	2yrs	Nessun dato	Nessun dato
Robert Warner	Director	less than a year	Nessun dato	Nessun dato
Arshad Khanani	Chair of Retina Scientific Advisory Board & Director	2yrs	Nessun dato	Nessun dato
Anat Loewenstein	Member of Scientific Advisory Board	2yrs	Nessun dato	Nessun dato
Pablo Villoslada	Member of Scientific Advisory Board	2yrs	Nessun dato	Nessun dato

2.0yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CR5 non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.

Oculis Holding Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG Announces Board and Committee Appointments

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Recent updates

Oculis Holding AG Announces Appointment of Daniel S. Char as Chief Legal Officer

Second quarter 2024 earnings released: CHF0.51 loss per share (vs CHF0.38 loss in 2Q 2023)

Oculis Holding AG Appoints Sharon Klier as Chief Development Officer

Oculis Holding AG to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Revenue and earnings growth

Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

Oculis Holding AG Announces Board and Committee Appointments

First quarter 2024 earnings released: CHF0.44 loss per share (vs CHF1.27 loss in 1Q 2023)

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $100 million.

Oculis Holding AG, Annual General Meeting, May 29, 2024

Oculis Holding AG has completed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG has filed a Follow-on Equity Offering in the amount of $58.75 million.

Oculis Holding AG Strengthens its Executive Leadership Team with the Appointment of Snehal Shah as President of Research & Development

Oculis Holding Ag Announces Positive Results from Phase 3 Optimize-1 Trial of Once Daily Ocs-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Full year 2023 earnings released: CHF2.97 loss per share (vs CHF12.95 loss in FY 2022)

New major risk - Revenue and earnings growth

Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery

Oculis Holding AG Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF ALPHA> Licaminlimab (OCS-02) in Dry Eye Disease

Third quarter 2023 earnings released: CHF0.48 loss per share (vs CHF3.29 loss in 3Q 2022)

Oculis Holding AG announced that it has received $71.18891 million in funding from a group of investors

Oculis Holding AG Announces Positive Phase 3 Stage 1 Diamond Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Oculis Holding to Present Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 Diamond Trial Results for Diabetic Macular Edema

New major risk - Revenue and earnings growth

Oculis Holding AG Appoints Rebecca Weil as Chief Commercial Officer

Second quarter 2023 earnings released: CHF0.38 loss per share (vs CHF3.29 loss in 2Q 2022)

Oculis Holding Ag Announces Positive Top Line Results from Its Phase 3 Optimize Trial with Ocs-01 Eye Drops

High number of new directors

Oculis Holding AG to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases

High number of new directors

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media